1. Ling, W, Shoptaw, S, Goodman-Meza, D. Depot buprenorphine injection in the management of opioid use disorder: from development to implementation. Subst Abuse Rehabil 2019;10:69–78. https://doi.org/10.2147/sar.s155843.
2. Smith, L, Mosley, J, Johnson, J, Nasri, M. Probuphine (buprenorphine) subdermal implants for the treatment of opioid-dependent patients. P t 2017;42:505–8.
3. Braeburn [Internet]. Titan pharmaceuticals and braeburn announce mutual termination of license agreement for probuphine® for opioid dependence. South San Francisco, CA, Plymouth Meeting, PA: Braeburnrx.com; 2018. Available from: https://braeburnrx.com/titan-pharmaceuticals-and-braeburn-announce-mutual-termination-of-license-agreement-for-probuphine-for-opioid-dependence/2018 [about 5 screens] [Accessed 9 Jan 2023].
4. European Medicines Agency. Assessment report: sixmo (buprenorphine). Amsterdam: Committee for Medicinal Products for Human Use (CHMP); 2019. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/sixmo.
5. Hedegaard, H, Minino, AM, Warner, M. Drug overdose deaths in the United States, 1999–2017. NCHS Data Brief 2018;329:1–8.